modelClazosentan

Diagram of Clazosentan

Extends from Pharmacolibrary.Drugs.ATC.C.C04AX33.

Information

name:Clazosentan
ATC code:C04AX33
route:intravenous
compartments:2
dosage:15mg
volume of distribution:40L
clearance:36L/h
other parameters in model implementation

Clazosentan is a selective endothelin A (ETA) receptor antagonist developed primarily for the prevention and treatment of cerebral vasospasm following aneurysmal subarachnoid hemorrhage (aSAH). It acts to inhibit vasoconstriction mediated by endothelin-1, thereby improving cerebral blood flow. Clazosentan is approved for use in some regions such as Japan, but not widely approved globally.

Pharmacokinetics

Pharmacokinetic parameters derived from healthy adult subjects after intravenous dosing.

References

  1. van Giersbergen, PL, et al., & Dingemanse, J (2007). Influence of ethnic origin and sex on the pharmacokinetics of clazosentan. Journal of clinical pharmacology 47(11) 1374–1380. DOI:10.1177/0091270007307337 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17906281

  2. Henrich, A, et al., & Krause, A (2021). PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT. Journal of pharmacokinetics and pharmacodynamics 48(2) 213–224. DOI:10.1007/s10928-020-09728-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33389549

  3. Volz, AK, et al., & Lehr, T (2019). Target-Mediated Population Pharmacokinetic Modeling of Endothelin Receptor Antagonists. Pharmaceutical research 37(1) 2–None. DOI:10.1007/s11095-019-2723-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31823033

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)